WASHINGTON, D.C. - When officials at Warner-Lambert Co. discovered they had a potentially life altering diabetes drug in production, they were thrilled. However, new documents show that research quickly showed the drug, Rezulin, caused liver damage.
Executives allegedly continued to promote the drug, which generated $2.1 billion in sales before being taken off the market three years after approval by officials at the Food and Drug Administration (FDA).
The drug was removed from store shelves because many liver-related deaths were linked to its use. New documents show Warner-Lambert executives may have known about this potentially lethal side effect from the beginning, but instead decided to conceal the information.
Pfizer Inc., which has since acquired Warner-Lambert, has turned information over to officials. More than 2,000 lawsuits have been filed for the 5,100 estimated Rezulin users.
Information from www.sfgate.com
I Was There: An Infection Preventionist on the COVID-19 Pandemic
April 30th 2025Deep feelings run strong about the COVID-19 pandemic, and some beautiful art has come out of those emotions. Infection Control Today is proud to share this poem by Carmen Duke, MPH, CIC, in response to a recent article by Heather Stoltzfus, MPH, RN, CIC.
From the Derby to the Decontam Room: Leadership Lessons for Sterile Processing
April 27th 2025Elizabeth (Betty) Casey, MSN, RN, CNOR, CRCST, CHL, is the SVP of Operations and Chief Nursing Officer at Surgical Solutions in Overland, Kansas. This SPD leader reframes preparation, unpredictability, and teamwork by comparing surgical services to the Kentucky Derby to reenergize sterile processing professionals and inspire systemic change.
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.